The hype around the health technology assessment review and the premise of the industry's 13 'discussion papers' both reflect a fundamental misunderstanding of how it is used in decision-making simply because more technical inputs can only ever mean more reasons to say no.
More HTA is not the solution because it will just create more reasons to say 'no'
November 11, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Another day, and another example of our system's shortcomings
July 21, 2025 - - Latest News -
Companies have all the power in this process, if they choose to use it
July 21, 2025 - - Latest News -
Trump says countries will avoid tariffs if manufacturing returns to the US
July 21, 2025 - - Latest News -
Mesoblast updates investors on the succesful US launch of cell medicine
July 20, 2025 - - Australian Biotech -
Company refuses FDA request to halt distribution of gene therapy
July 20, 2025 - - Latest News -
Australian researcher awarded Gilead Sciences global grant to explore novel approach in breast cancer
July 18, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 17 July
July 17, 2025 - - Podcast